A Study of MK-3009 in Japanese Patients With Skin or Blood Stream

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The study investigates the efficacy and safety of MK-3009 in participants with skin infections, septicemia and right-sided infective endocarditis (RIE) caused by methicillin-resistant Staphylococcus aureus (MRSA).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00770341
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 3
Start date	September 2008
Completion date	February 2010

See also
	Status	Clinical Trial	Phase
	Withdrawn	`NCT02899702` - Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children	Phase 4
	Completed	`NCT00352612` - Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections	Phase 4
	Completed	`NCT00279864` - The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection	N/A
	Completed	`NCT00735839` - V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)	Phase 1
	Completed	`NCT00814151` - MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial	N/A
	Completed	`NCT02812446` - Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development	N/A
	Completed	`NCT00846105` - Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA)	N/A
	Completed	`NCT02284555` - Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)	Phase 4
	Completed	`NCT01592214` - Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73	Phase 1
	Completed	`NCT01827358` - Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants	Phase 2
	Completed	`NCT00730028` - Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus	Phase 2
	Completed	`NCT00729937` - Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"	Phase 2/Phase 3